NCT06480201View on ClinicalTrials.gov

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HealthyMajor Depressive DisorderTreatment Resistant Depression
Interventions
DRUG

Ketamine

Ketamine infusion amount is dictated by BMI, sex, and age.

OTHER

Saline

Saline infusion amount is dictated by BMI, sex, and age.

Trial Locations (2)

77024

RECRUITING

Wells Medicine, Houston

77030

RECRUITING

Baylor College of Medicine Jamail Specialty Care Center, Houston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Baylor College of Medicine

OTHER